ABSTRACT
Objetivo. Determinar el grado de aceptación de un Pro grama de Optimización del Uso de Antimicrobianos (PROA) en un Servicio de Medicina Intensiva (SMI), y evaluar su efecto sobre el consumo de antibióticos, indicadores de calidad y re sultados clínicos. Pacientes y métodos. Descripción retrospectiva de las intervenciones propuestas por un PROA. Comparación de uso de antimicrobianos, indicadores de calidad y seguridad frente a un periodo sin PROA. Se realizó en un SMI polivalente de un Hospital Universitario mediano (600 camas). Se estudió a pacientes ingresados por cualquier causa en el SMI durante el periodo PROA en los que se hubiera obtenido una muestra di rigida al diagnóstico de una potencial infección, o se hubieran iniciado antimicrobianos. Se elaboraron recomendaciones no impositivas para mejorar la prescripción antimicrobiana (es tructura audit and feedback) y se procedió a su registro du rante periodo PROA (15 meses, octubre 2018diciembre 2019). Comparación de indicadores en un periodo con PROA (abril junio 2019) y sin PROA (abriljunio 2018). Resultados. Se emitieron 241 recomendaciones sobre 117 pacientes, el 67% de ellas de tipo desescalada terapéutica. La aceptación de las recomendaciones fue elevada (96.3%). En el periodo PROA se redujo el número medio de antibióticos por paciente (3.3±4.1 vs 2.4±1.7, p=0.04) y los días de tratamiento (155 DOT/100 PD vs 94 DOT/100 PD, p <0.01) (AU)
Objective. We aim to evaluate the adherence rate to an Antimicrobial Stewardship Program (ASP) in an Intensive Care Unit (ICU), and to assess its effect on the use of antibiotics, quality indicators and clinical outcomes. Patients and methods. Retrospective description of the interventions proposed by the ASP. We compared antimi crobial use, quality and safety indicators in an ASP versus a non-ASP period. The study was performed in a polyvalent ICU of a medium-size University Hospital (600 beds). We studied patients admitted to the ICU for any cause during the ASP pe riod, provided that a microbiological sample aiming to diag nose a potential infection has been drawn, or antibiotics have been started. We elaborated and registered of non-mandatory recommendations to improve antimicrobial prescription (audit and feedback structure) and its registry during the ASP peri od (15 months, October 2018-December 2019). We compared indicators in a period with ASP (April-June 2019) and without ASP (April-June 2018). Results. We issued 241 recommendations on 117 pa tients, 67% of them classified as de-escalation type. The rate of adherence to the recommendations was high (96.3%). In the ASP period, the mean number of antibiotics per patient (3.3±4.1 vs 2.4±1.7, p=0.04) and the days of treatment (155 DOT/100 PD vs 94 DOT/100 PD, p <0.01) (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Antimicrobial Stewardship , Intensive Care Units , Drug Resistance, Microbial , Critical Care , Retrospective StudiesABSTRACT
BACKGROUND: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU. METHODS: This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group. RESULTS: Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). KaplanâMeier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways. CONCLUSIONS: A blood miRNA classifier improves the early prediction of fatal outcomes in critically ill COVID-19 patients.
Subject(s)
COVID-19 , MicroRNAs , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Prospective Studies , Retrospective Studies , COVID-19/diagnosis , COVID-19/genetics , Critical Illness , Biomarkers , Intensive Care UnitsABSTRACT
INTRODUCTION: Critical COVID-19 survivors have a high risk of respiratory sequelae. Therefore, we aimed to identify key factors associated with altered lung function and CT scan abnormalities at a follow-up visit in a cohort of critical COVID-19 survivors. METHODS: Multicenter ambispective observational study in 52 Spanish intensive care units. Up to 1327 PCR-confirmed critical COVID-19 patients had sociodemographic, anthropometric, comorbidity and lifestyle characteristics collected at hospital admission; clinical and biological parameters throughout hospital stay; and, lung function and CT scan at a follow-up visit. RESULTS: The median [p25-p75] time from discharge to follow-up was 3.57 [2.77-4.92] months. Median age was 60 [53-67] years, 27.8% women. The mean (SD) percentage of predicted diffusing lung capacity for carbon monoxide (DLCO) at follow-up was 72.02 (18.33)% predicted, with 66% of patients having DLCO<80% and 24% having DLCO<60%. CT scan showed persistent pulmonary infiltrates, fibrotic lesions, and emphysema in 33%, 25% and 6% of patients, respectively. Key variables associated with DLCO<60% were chronic lung disease (CLD) (OR: 1.86 (1.18-2.92)), duration of invasive mechanical ventilation (IMV) (OR: 1.56 (1.37-1.77)), age (OR [per-1-SD] (95%CI): 1.39 (1.18-1.63)), urea (OR: 1.16 (0.97-1.39)) and estimated glomerular filtration rate at ICU admission (OR: 0.88 (0.73-1.06)). Bacterial pneumonia (1.62 (1.11-2.35)) and duration of ventilation (NIMV (1.23 (1.06-1.42), IMV (1.21 (1.01-1.45)) and prone positioning (1.17 (0.98-1.39)) were associated with fibrotic lesions. CONCLUSION: Age and CLD, reflecting patients' baseline vulnerability, and markers of COVID-19 severity, such as duration of IMV and renal failure, were key factors associated with impaired DLCO and CT abnormalities.
Subject(s)
COVID-19 , Pulmonary Emphysema , Humans , Female , Middle Aged , Male , Critical Illness , Follow-Up Studies , COVID-19/complications , Disease Progression , Lung/diagnostic imagingABSTRACT
Background: The clinical heterogeneity of COVID-19 suggests the existence of different phenotypes with prognostic implications. We aimed to analyze comorbidity patterns in critically ill COVID-19 patients and assess their impact on in-hospital outcomes, response to treatment and sequelae. Methods: Multicenter prospective/retrospective observational study in intensive care units of 55 Spanish hospitals. 5866 PCR-confirmed COVID-19 patients had comorbidities recorded at hospital admission; clinical and biological parameters, in-hospital procedures and complications throughout the stay; and, clinical complications, persistent symptoms and sequelae at 3 and 6 months. Findings: Latent class analysis identified 3 phenotypes using training and test subcohorts: low-morbidity (n=3385; 58%), younger and with few comorbidities; high-morbidity (n=2074; 35%), with high comorbid burden; and renal-morbidity (n=407; 7%), with chronic kidney disease (CKD), high comorbidity burden and the worst oxygenation profile. Renal-morbidity and high-morbidity had more in-hospital complications and higher mortality risk than low-morbidity (adjusted HR (95% CI): 1.57 (1.34-1.84) and 1.16 (1.05-1.28), respectively). Corticosteroids, but not tocilizumab, were associated with lower mortality risk (HR (95% CI) 0.76 (0.63-0.93)), especially in renal-morbidity and high-morbidity. Renal-morbidity and high-morbidity showed the worst lung function throughout the follow-up, with renal-morbidity having the highest risk of infectious complications (6%), emergency visits (29%) or hospital readmissions (14%) at 6 months (p<0.01). Interpretation: Comorbidity-based phenotypes were identified and associated with different expression of in-hospital complications, mortality, treatment response, and sequelae, with CKD playing a major role. This could help clinicians in day-to-day decision making including the management of post-discharge COVID-19 sequelae. Funding: ISCIII, UNESPA, CIBERES, FEDER, ESF.
ABSTRACT
Antecedentes. La infección fúngica invasiva es una causa importante de morbimortalidad en los pacientes con quemaduras graves. Los avances en el tratamiento del paciente quemado crítico han llevado a una supervivencia mayor, pero, a su vez, a un aumento de las complicaciones sépticas, en especial de las infecciones fúngicas, con un incremento de las infecciones por diferentes especies de Candida. Sin embargo, algunos hongos oportunistas, como Trichosporon asahii, están emergiendo como causa importante de infección nosocomial. Caso clínico. Presentamos un caso de infección nosocomial por T. asahii en un paciente quemado crítico tratado de forma exitosa con voriconazol. El tratamiento de las infecciones fúngicas invasivas en el paciente quemado, desde su diagnóstico hasta la elección de la mejor opción terapéutica, continúa siendo un desafío. El diagnóstico y el tratamiento tempranos de estas se asocia a un mejor pronóstico. En la discusión del caso hacemos referencia a la experiencia publicada y a las pautas de tratamiento actual. Conclusiones. Debido a la dificultad para el diagnóstico de las micosis invasivas y su asociación con una alta mortalidad, en aquellos pacientes susceptibles de padecer una trichosporonosis se debe mantener un alto grado de sospecha y vigilancia clínica para el diagnóstico de esta infección, incluidos los pacientes quemados. Su presencia en las muestras clínicas de este tipo de pacientes debe ser tenida en cuenta porque puede preceder a una infección invasiva (AU)
Background. Invasive fungal infection is an important cause of morbimortality in patients with severe burns. The advances in burn care therapy have considerably extended the survival of seriously burned patients, exposing them to infectious complications, notably fungal infections, with increased recognition of invasive infections caused by Candida species. However, some opportunistic fungi, like Trichosporon asahii, have emerged as important causes of nosocomial infection. Case report. A case of nosocomial infection due to T. asahii in a severely ill burned patient successfully treated with voriconazole is presented. The management of invasive fungal infections in burned patients, from diagnosis to selection of the therapeutic protocol, is often a challenge. Early diagnosis and treatment are associated with a better prognosis. In this case report, current treatment options are discussed, and a review of previously published cases is presented. Conclusions. Due to the difficulty in the diagnosis of invasive mycoses and their high associated mortality rates, it is advisable to keep a high degree of clinical suspicion of trichosporonosis in susceptible patients, including burned patients. The isolation of T. asahii in clinical specimens of this type of host must raise clinical alert, since it may precede an invasive infection (AU)
Subject(s)
Female , Humans , Middle Aged , Trichosporon/isolation & purification , Trichosporonosis/diagnosis , Burns/complications , Antifungal Agents/therapeutic use , Cross Infection/diagnosis , /epidemiologyABSTRACT
BACKGROUND: Invasive fungal infection is an important cause of morbimortality in patients with severe burns. The advances in burn care therapy have considerably extended the survival of seriously burned patients, exposing them to infectious complications, notably fungal infections, with increased recognition of invasive infections caused by Candida species. However, some opportunistic fungi, like Trichosporon asahii, have emerged as important causes of nosocomial infection. CASE REPORT: A case of nosocomial infection due to T. asahii in a severely ill burned patient successfully treated with voriconazole is presented. The management of invasive fungal infections in burned patients, from diagnosis to selection of the therapeutic protocol, is often a challenge. Early diagnosis and treatment are associated with a better prognosis. In this case report, current treatment options are discussed, and a review of previously published cases is presented. CONCLUSIONS: Due to the difficulty in the diagnosis of invasive mycoses and their high associated mortality rates, it is advisable to keep a high degree of clinical suspicion of trichosporonosis in susceptible patients, including burned patients. The isolation of T. asahii in clinical specimens of this type of host must raise clinical alert, since it may precede an invasive infection.